Icrucumab

Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors[1].

Product Specifications

CAS Number

[1024603-92-6]

Product Name Alternative

Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1

UNSPSC

12352203

Target

VEGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/icrucumab.html

Purity

99.99

Solubility

10 mM in DMSO

Smiles

[Icrucumab]

Molecular Weight

(146.68 kDa)

References & Citations

[1]LoRusso PM, et al. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32 (2) :303-11.